Patient-provider Decision Aid for HIV Post-exposure Prophylaxis Following Sexual Assault
Launched by UNIVERSITY OF ARKANSAS · Nov 14, 2023
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is testing a new digital tool designed to help patients and their healthcare providers make decisions about HIV post-exposure prophylaxis (PEP) after a sexual assault. The tool includes important information about HIV risk, educational resources on how effective PEP can be, and allows patients to express their priorities, such as concerns about privacy, health, or costs. The goal is to create a more personalized and informed experience for patients seeking care.
To participate in this trial, individuals must be at least 18 years old, seeking help from a specific healthcare center after a sexual assault, and able to communicate in English. Participants should also have approached the healthcare center within 72 hours after potential exposure to HIV. Those who join can expect to engage with the digital tool and provide feedback on how it helps them in making decisions about their health. This study is currently recruiting participants, and your involvement could contribute to improving care for others in similar situations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years or older
- • seeking care from DCFNE following sexual assault
- • able to provide consent and participate in the study in English
- • meets CDC criteria for HIV PEP \[a) seeking care within 72 hours of potential exposure, b) potential exposure\]
- Exclusion Criteria:
- • \<18 years old
- • Does not meet CDC criteria for HIV PEP \[seeking care \>72 hours after assault, assault with minimal/low exposure risk\]
- • unable to complete study requirements in English
About University Of Arkansas
The University of Arkansas is a leading research institution dedicated to advancing healthcare through innovative clinical trials. With a commitment to excellence in research and education, the university facilitates a collaborative environment that encourages interdisciplinary studies and the development of cutting-edge therapies. Its clinical trial programs leverage state-of-the-art facilities and expert faculty, aiming to improve patient outcomes and contribute to the body of medical knowledge. The university fosters partnerships with healthcare providers and industry stakeholders, ensuring rigorous ethical standards and adherence to regulatory requirements in all research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Washington, District Of Columbia, United States
Washington, District Of Columbia, United States
Patients applied
Trial Officials
Jocelyn Anderson
Principal Investigator
UAMS
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported